Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

olutasidenib 1lenvatinib 1Sevoflurane 1Oxaliplatin 1Nutritional Status 1Midazolam 1Meperidine 1Folfox protocol 1Etomidate 1Enteral Nutrition 1Eicosapentaenoic Acid 1Diet 1Desflurane 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C9 1Cytochrome P-450 CYP2C8 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP2B6 1Cytochrome P-450 CYP1A2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Cholangiocarcinoma × olutasidenib × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡